Consistent with these prognostic associations, HOTAIRM1 was recently shown by other investigators to be aberrantly expressed in glioblastoma [21] and associated with shorter survival of glioma patients [21, 24, 26]. Here, HOTAIRM1 is linked to central nervous system cancer.